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Colchicine has been used to treat gout and, more recently, to effectively prevent
autoinflammatory diseases and both primary and recurrent episodes of pericarditis. The
anti-inflammatory action of colchicine seems to result from irreversible inhibition of
tubulin polymerization and microtubule (MT) assembly by binding to the tubulin
heterodimer, avoiding the signal transduction required to the activation of the entire
NLRP3 inflammasome. Emerging results show that the MT network is a potential
regulator of cardiac mechanics. Here, we investigated how colchicine impacts in tubulin
folding cofactors TBCA, TBCB, and TBCE activities. We show that TBCA is abundant
in mouse heart insoluble protein extracts. Also, a decrease of the TBCA/β-tubulin
complex followed by an increase of free TBCA is observed in human cells treated with
colchicine. The presence of free TBCA is not observed in cells treated with other anti-
mitotic agents such as nocodazole or cold shock, neither after translation inhibition
by cycloheximide. In vitro assays show that colchicine inhibits tubulin heterodimer
dissociation by TBCE/TBCB, probably by interfering with interactions of TBCE with
tubulin dimers, leading to free TBCA. Manipulation of TBCA levels, either by RNAi or
overexpression results in decreased levels of tubulin heterodimers. Together, these data
strongly suggest that TBCA is mainly receiving β-tubulin from the dissociation of pre-
existing heterodimers instead of newly synthesized tubulins. The TBCE/TBCB+TBCA
system is crucial for controlling the critical concentration of free tubulin heterodimers
and MT dynamics in the cells by recycling the tubulin heterodimers. It is conceivable
that colchicine affects tubulin heterodimer recycling through the TBCE/TBCB+TBCA
system producing the known benefits in the treatment of pericardium inflammation.
Keywords: colchicine, tubulin cofactors, TBCA, TBCB, TBCE, tubulin heterodimer dissociation,
microtubule cytoskeleton
INTRODUCTION
Microtubules (MTs) are dynamic polymers of heterodimers of α- and β-tubulin that grow and
shrink by the addition and removal of tubulin heterodimers at their ends. MT arrays are present
in almost all eukaryotic cells constituting, together with actin and intermediate filaments, the
cytoskeleton. MTs, in crosstalk with other cytoskeleton members, play many roles in cell spatial
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organization, the establishment of cellular asymmetries
and polarity, intracellular transport, cell migration, and
morphogenesis (Dogterom and Koenderink, 2019). These
polymers are also the main constituents of complex structures
such as the mitotic and meiotic spindles, centrioles/basal
bodies, and the ciliary axoneme, being involved in cell division,
motility, and signaling. The diversity of MT functions depends
on the biochemical variety of tubulin pools generated either
by the constitutive or tissue-specific expression patterns of the
tubulin gene family members and by tubulin post-translational
modifications (Roll-Mecak, 2020). Additionally, MTs are
modulated by a vast number of MT-binding proteins with
multiple activities (for review, Goodson and Jonasson, 2018).
In vivo, the dynamic behavior of MTs relies on the existence
of competent tubulin heterodimers originated either from de
novo synthesis or MTs recycling (for review Gonçalves et al.,
2010). For this, eukaryotic cells are equipped with a few
molecular chaperones (cytosolic chaperonin CCT (cytosolic
chaperonin-containing TCP1) and its cochaperone prefoldin)
(Cowan and Lewis, 2001; Lopez et al., 2015), and a group of
specific tubulin cofactors (TBCA-E) (Lewis et al., 1997; Lopez-
Fanarraga et al., 2001). Along with tubulin folding, tubulin
cofactors assist tubulin heterodimer assembly/dissociation, as
well as tubulin degradation (Lewis et al., 1997; Lopez-Fanarraga
et al., 2001; Kortazar et al., 2007; Voloshin et al., 2010). Therefore,
in vivo, tubulin cofactors play pivotal roles in maintaining
tubulin pools and tubulin heterodimers recycling/degradation
by controlling their native structure’s quality. This also indicates
that TBCs can be involved in MT cytoskeleton remodeling
and the assembly/disassembly of specific MT populations and
structures. The overexpression of TBCD and TBCE completely
disrupts the MT cytoskeleton (Martín et al., 2000; Kortazar
et al., 2006). TBCD and TBCE are capable of dissociating the
tubulin heterodimer by themselves, but in the case of TBCE, its
dissociation activity is highly increased by the presence of TBCB
(Serna and Zabala, 2016). In fact, TBCB and TBCE stabilize the
α-tubulin subunit after dimer dissociation originating a ternary
complex TBCE/TBCB/α-tubulin (Carranza et al., 2013; Serna
et al., 2015). Both TBCB and TBCE share a CAP-Gly and a
UBL (ubiquitin-like) domain in their primary structures, but
in inverted order (Serna and Zabala, 2016). The dissociation
complex may also be involved in α-tubulin degradation. The
UBL domains of TBCE and TBCB present a protruding
arrangement suggesting the possibility of interacting with the
proteasome (Serna et al., 2015), as mechanistically detailed in the
review by Serna and Zabala (2016).
After tubulin heterodimer dissociation, cells avoid the toxic
effect of β-tubulin (Archer et al., 1995; Abruzzi et al., 2002) by
stabilizing it through the association with TBCD or/and TBCA
(Carranza et al., 2013; Serna et al., 2015). In budding yeast,
TBCA (Rbl2p) can rescue cells from β-tubulin overexpression
and is required for meiosis (Archer et al., 1995). In contrast,
in fission yeast, TBCA (Alp31) is necessary for the integrity
of MTs and consequently for growth polarity (Radcliffe et al.,
2000). In vitro, TBCA is dispensable for tubulin folding
(Abruzzi et al., 2002), which contrasts with the observation
that, in human cell lines, TBCA is encoded by an essential
gene (Nolasco et al., 2005). Depletion of TBCA in human
cells causes a decrease in soluble tubulin, modifications in
MT and actin cytoskeletons organization, and G1 cell cycle
arrest. Similarly, TBCA mutants in Schizosaccharomyces pombe
and Arabidopsis thaliana present unstable and defective MTs
structures, compromised MT organization, and cell morphology
alterations (Archer et al., 1995; Radcliffe et al., 2000; Kirik et al.,
2002; Steinborn et al., 2002).
Although the molecular mechanisms underlying the role of
tubulin cofactors in tubulin heterodimers’ maturation, tubulin
recycling, and tubulin degradation have been progressively
elucidated, the complete scenario of their roles in vivo is far
from being completely understood. Different tubulin cofactors
seem to play critical roles in invertebrate and vertebrate brain
function/maintenance, development, and morphogenesis (Shern
et al., 2003; Okumura et al., 2015; Chen et al., 2016), which is
highlighted by their association with diverse neurodegenerative
diseases like the giant axonal neuropathy (GAN) (Wang et al.,
2005; Yang et al., 2007), amyotrophic lateral sclerosis (Helferich
et al., 2018), motor neuronopathy (Martin et al., 2002; Schaefer
et al., 2007; Bellouze et al., 2014), progressive neurodegenerative
encephalopathy with distal spinal muscular atrophy (Sferra
et al., 2016) and eventually with tauopathies (Fujiwara et al.,
2020). Other syndromes, such as the recessive disorder Sanjad-
Sakati syndrome (SSS), and the autosomal recessive Kenny-
Caffey syndrome, were associated with TBCE mutations (Parvari
et al., 2002). In general, the cells from patients with these
syndromes show lower MT density/disrupted MT networks,
perturbed MT polarity, and Golgi apparatus fragmentation
(Martin et al., 2002; Schaefer et al., 2007; Bellouze et al.,
2014; Sferra et al., 2016). TBCs have also been involved in
breast cancer development suggesting that dysregulation of the
tubulin heterodimer pool may impact tumor cell phenotypes
and response to chemotherapy (Vadlamudi et al., 2005; Hage-
Sleiman et al., 2010). The activity of tubulin cofactors has
also been associated with cilia biology (Grayson et al., 2002;
Lopez-Fanarraga et al., 2007; Fanarraga et al., 2010a). The
complexity of the roles of tubulin cofactors indicates that
these proteins may also have non-tubulin-folding activities.
For example, TBCB and TBCD localize at the centrosome,
and changes in these cofactors affect centrosomal γ-tubulin
(Vadlamudi et al., 2005; Cunningham and Kahn, 2008; Fanarraga
et al., 2010a). In S. pombe, genetic interactions between TBCD
mutant forms with the kinetochore CENP-B-like protein and
spindle components (Fedyanina et al., 2006) suggest that TBCD
may play essential functions at these structures. Also, disassembly
of tight and adherent junctions followed by cell dissociation from
the epithelial monolayer is observed in TBCD overexpression
backgrounds (Shultz et al., 2008). The study of the complexity
of regulatory mechanisms involving tubulin cofactors has been
neglected. Still, the activity of TBCB is regulated by post-
translational modifications like phosphorylation by a p21-
activated kinase (Pak1) that is essential for the polymerization
of new MTs (Vadlamudi et al., 2005). Similar to tau and α-
tubulin, TBCB also undergoes nitration, which inhibits the
polymerization of new MTs (Rayala et al., 2007) by inhibiting
TBCB phosphorylation. TBCB also seems to be regulated by
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the non-coding micro RNA miR-1825 (Helferich et al., 2018),
whereas a non-coding antisense RNA regulates TBCA during
testis maturation (Nolasco et al., 2012).
MTs and/or tubulin are the targets for many small molecules
that act as anti-mitotic agents. However, how these compounds
interfere with the in vivo activities of TBCs is unknown. The
importance of investigating this putative interplay relies not only
on the fact that valuable information about the mechanisms
underlying MT dynamics in vivo can be acquired but primarily
because these molecules are clinically significant. For example,
the anti-mitotic drug colchicine has been used as an anti-
inflammatory and anti-fibrotic drug (for review, Roberts, 1987;
Dalbeth et al., 2014). The uses for colchicine include chronic
inflammatory diseases as gouty arthritis (Roberts, 1987; Dalbeth
et al., 2014), the familial Mediterranean fever (FMF) (Goldfinger,
1972), the Behcet’s disease (Yurdakul et al., 2001), a variety of
dermatological conditions (e.g., epidermolysis bullosa acquisita
and aphthous stomatitis), and other fibro-inflammatory diseases
(Addrizzo-Harris et al., 2002; Martínez et al., 2015; Solak et al.,
2017). In the last years, colchicine has also been emerging as a
first-line drug to treat pericardial diseases. The anti-inflammatory
properties of colchicine and the absence of effective drugs to treat
COVID-19 lead to the idea that the use of colchicine may be
efficient in COVID-19 treatment (Corral et al., 2020; Nasiripour
et al., 2020). Therefore, several colchicine randomized controlled
trials in COVID-19 are ongoing1.
The anti-inflammatory action of colchicine seems to result
from a compromised MT cytoskeleton that affects several
inflammatory pathways in cells that mediate immune response
like the adhesion and recruitment of neutrophils, superoxide
production, inflammasome activation, the RhoA/Rho effector
kinase (ROCK) pathway, and the tumor necrosis factor-alpha
(TNF-α)-induced nuclear factor κB (NF-κB) pathway (for
review Angelidis et al., 2018).
Virtually nothing is known about colchicine’s impact on
the recycling cycle and quality control of tubulin heterodimers
conducted by TBCs. Here we show that the exposure of human
cells to colchicine causes a decrease of the TBCA/β-tubulin
complex to vestigial levels followed by an increase of free
TBCA. Free TBCA was never observed in human control cells
nor in cells exposed to other anti-mitotic MT depolymerizing
agents like nocodazole and cold-shock, or even after translation
inhibition by cycloheximide. The appearance of free TBCA is
accompanied by an increase in free soluble tubulin heterodimers
due to MT depolymerization. We show, in in vitro assays,
that colchicine inhibits tubulin heterodimer dissociation by
TBCE/TBCB, affecting heterodimer recycling/quality control.
This result strongly suggests that MT depolymerization by
colchicine treatment is not only due to the conformational
alteration of the tubulin heterodimer but also to the inability
of cofactors to recycle these heterodimers, which also explains
the irreversible colchicine action. The manipulation of TBCA
levels, either by RNAi or by overexpression, causes the decrease
of tubulin heterodimers. Collectively, our data strongly suggest
1https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=
&state=&city=&dist
that TBCA is mainly receiving β-tubulin from the dissociation of
pre-existing heterodimers instead of newly synthesized tubulins,
which is supported by the observations using the translation
inhibitor cycloheximide. Thus, we show that the system
TBCE/TBCB+TBCA is crucial for the control of the critical
concentration of free tubulin heterodimers and MT dynamics
in the cells. The finding that colchicine affects the tubulin
heterodimer recycling/degradation system TBCE/TBCB+TBCA
should be taken into account in the context of colchicine’s
therapeutic benefits as an anti-inflammatory drug.
RESULTS
Colchicine Causes the Decrease of the
TBCA/β-Tubulin Complex and the
Detection of Free TBCA in HeLa Cells
In addition to tubulin folding, TBCs are also involved in
tubulin heterodimer recycling and degradation, regulating MT
dynamics by controlling the tubulin heterodimer pool competent
to polymerize (Serna et al., 2015). MTs and/or tubulin are
targets for many small molecules that can stabilize or destabilize
these polymers due to their ability to increase or decrease MT
assembly at high concentrations. These molecules also strongly
compromise MT dynamics at concentrations 10- to 100-fold
lower than those required to affect MT mass (for review, see
Dumontet and Jordan, 2010).
Previously, we showed that TBCA knockdown causes a
decreased amount of α- and β-tubulin, G1 cell cycle arrest, and
cell death in human cell lines (Nolasco et al., 2005). Contrary
to TBCB, TBCE, and TBCD, TBCA is not able to dissociate
the native tubulin heterodimer by itself (Martín et al., 2000;
Kortazar et al., 2006, 2007; Carranza et al., 2013), but after
tubulin heterodimer dissociation, TBCA forms a stable complex
with β-tubulin, being responsible for its recycling/degradation
(Kortazar et al., 2007).
To investigate how the in vivo activities of TBCA are
affected by MT depolymerizing agents, we treated HeLa cells
with: a) colchicine (5 µM), a tubulin-binding anti-mitotic drug,
with clinical relevance, that depolymerizes MTs irreversibly;
b) nocodazole (30 µM), a tubulin-binding anti-mitotic drug,
a rapid and reversible inhibitor of MT polymerization (De
Brabander et al., 1976); and c) cold shock, low temperature, that is
well-established to promote MT depolymerization (Weisenberg,
1972; Shelanski et al., 1973). The exposure of cells to all
different treatments was performed for 15, 30, and 60 min
after which soluble native protein extracts were prepared and
analyzed by 6% (w/v) non-denaturing-PAGE. As migration
markers, purified α/β-tubulin heterodimers and TBCA were
simultaneously analyzed with the protein extracts of cells treated
with distinct MT depolymerizing agents (Figure 1). These
analyses were followed by western blot using antibodies against
TBCA and β-tubulin (Figure 1). As expected for purified
TBCA (free TBCA), we observed a unique band in the lane
(Figures 1A1,B1,C1). However, according to Llosa et al. (1996)
when protein extracts from cells are analyzed in this type of
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FIGURE 1 | Colchicine treatment triggers the appearance of free TBCA in HeLa cells. HeLa cells were treated with different microtubule depolymerizing agents
(colchicine, nocodazole, and cold shock) for 15, 30, and 60 min. After each treatment, native protein extracts were prepared, and equal amounts of soluble protein
extracts (30 µg) were analyzed by non-denaturing gel electrophoresis (6% native-PAGE) followed by western blot with antibodies directed to TBCA (A1,B1,C1) and
β-tubulin (A2,B2,C2). Representative images of the native-PAGE show that: free TBCA was not detected in all-control cells (untreated) (A1,B1,C1); upon colchicine
treatment, the amount of TBCA/β-tubulin complex progressively decreases over the indicated time-frames reaching the lowest level at 60 min which is accompanied
by the detection of free TBCA in the cell extract (A1,A3: *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001); under nocodazole treatment TBCA/β-tubulin
complex also decreases at 60 min to exposure of cells to this anti-mitotic drug, but free TBCA is never detected (B1,B3: *p < 0.05 and **p < 0.0001); and under
cold shock treatment the levels of the TBCA/β-tubulin complex are maintained (C1,C3). The soluble α/β-tubulin levels increase in response to MT depolymerization
(A2,B2,C2). The graphs in panels (A3) (colchicine), (B3) (nocodazole), and (C3) (cold-shock), show the relative units in percentage of TBCA/β-tubulin complex and
free TBCA levels in comparison to control cells (100%). Statistical significance was calculated using a t-test and the p-values were determined in comparison to the
time 0 min (control). The graphic bars are the mean s.d. (error bars) of three independent assays. For each treatment, the MT depolymerization was confirmed by
indirect immunofluorescence using an antibody against α-tubulin (A4,B4,C4) (the DNA was stained with DAPI, scale bar 10 µm).
native gels, it is expected that the anti-TBCA sera will be able to
detect not only the free TBCA but also a faster migrating band
corresponding to the TBCA/β-tubulin complex.
Interestingly, in control extracts from HeLa cells
(Figures 1A1,B1,C1; lane C), the band corresponding to
free TBCA is never observed. A faster migrating band, probably
corresponding to the TBCA/β-tubulin complex, is clearly
visible. To demonstrate that in our analysis, we could not
use the antibody against β-tubulin as this only detects the
α/β-tubulin heterodimer but not the TBCA/β-tubulin complex
(Figures 1A2,B2,C2). This is probably a consequence of
the β-tubulin epitope, recognized by this antibody, being
hidden in the quaternary structure of the TBCA/β-tubulin
complex. Therefore, to prove that the faster migrating band
corresponds to the TBCA/β-tubulin complex, we excised this
band from a 6% (w/v) Native-PAGE stained with Coomassie
Brilliant Blue and re-analyzed it on a 16.5% (w/v) Tricine–
SDS–PAGE. Then western-blot analysis was performed using
specific antibodies to TBCA and β-tubulin. This analysis
showed that the extracted band possesses β-tubulin and TBCA,
confirming that it corresponds to the TBCA/β-tubulin complex
(Supplementary Figure 1).
Curiously, these results clearly show that, in HeLa control
cells, most TBCA is in a complex with β-tubulin, and these cells
do not seem to contain a free pool of TBCA. The results in HeLa
cells exposed for different times to cold shock 4◦C (Figure 1C1)
are like those observed in control cells, and the amount of the
TBCA/β-tubulin complex does not significantly change over the
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studied time lapse (see panel C3). On the contrary, the amount
of soluble tubulin heterodimer increases reaching the highest
level at 60 min after exposure to 4◦C (Figure 1C2), suggesting
that depolymerized MTs contribute to the rise of the soluble
tubulin pool (heterodimers). In fact, the detection of α-tubulin
by immunofluorescence (IF) microscopy in HeLa control cells
and cells exposed to cold shock for 60 min show that in cells
subject to 4◦C the MT arrays are dismantled, even though
their regular shape is maintained (Figure 1C4). In some cells,
soluble free tubulin concentrates at specific sites of the cytoplasm
(Figure 1C4 arrows). Noteworthy, depolymerization of MTs
caused by nocodazole or colchicine as revealed by IF microscopy
analysis (see Figures 1A4,B4) is accompanied by the decrease of
the amount of the TBCA/β-tubulin complex (Figures 1A1,B1).
However, this decrease is much more accentuated in HeLa
cells subjected to colchicine treatment (18 ± 16%) than in
those subjected to nocodazole (48 ± 4%) for the same period
(Figures 1A3,B3).
Moreover, the reduction of the amount of TBCA/β-tubulin
complex initiates at 15 min of colchicine and nocodazole
treatment (Figures 1A1,A3). Strikingly, in cells treated with
colchicine, the decrease of the amount of TBCA/β-tubulin
complex is closely followed by the gradual appearance of a
band corresponding to free TBCA (Figures 1A1,A3). This
band is not observed in HeLa cells treated with nocodazole,
indicating a specific effect of the colchicine action in HeLa
cells. Moreover, in agreement with the IF microscopy data, a
progressive increase in the amount of α/β-tubulin heterodimer
is observed either in nocodazole or colchicine HeLa treated cells
during the studied time course (see Figures 1A3,B3). Thus,
the interesting observation that colchicine dramatically increases
the levels of free TBCA is not a direct consequence of MT
depolymerization.
For all conditions the soluble protein extracts previously tested
in native gels were subjected to 16.5% (w/v) Tricine–SDS–PAGE
followed by detection with anti-TBCA and β-tubulin antibodies
upon western blot analysis. The results (Supplementary
Figure 2) show no significant alterations of TBCA levels and
a slight increase in β-tubulin levels compared to the levels of
these proteins in control cells. Of note, the increase of α/β-
tubulin heterodimers, in response to the MT depolymerization,
is not as clearly observed as in native gels, since in these we
analyze the amount of all β-tubulin polypeptides regardless of
its origin (α/β-tubulin, TBCA/β-tubulin or other). Therefore, the
variations in the amount of free TBCA and the TBCA/β-tubulin
complex observed in colchicine and nocodazole treated cells
(Figures 1A1,B1) do not correspond to changes in the total
amount of soluble TBCA and β-tubulin proteins in HeLa
cells treated with these different MT depolymerizing agents
in the indicated time-frames. These data clearly show that
the decreased amounts of the TBCA/β-tubulin complex are
not the result of reduced levels of any of the two proteins
in HeLa cells. Moreover, in the time course of all the
conditions studied, the soluble β-tubulin levels do not change
significantly (see Supplementary Figure 2), but the native
analysis indicates that the soluble α/β-tubulin heterodimer
amount clearly increases (see Figures 1A2,B2,C2). This strongly
suggests that at least β-tubulin may be displaced to a complex not
visible in our conditions.
Free TBCA Is Not a Consequence of
Protein Translation Inhibition
Since there is evidence that low doses of colchicine prevent
mRNA translation by promoting polysome disaggregation
(Walker and Whitfield, 1984), we put forward the hypothesis
that the appearance of free TBCA in cells treated with colchicine
could be related to the absence of newly synthesized tubulin. To
assess this hypothesis, we analyzed the effect of the eukaryotic
translational elongation inhibitor cycloheximide in the amounts
of TBCA/β-tubulin complex as well as free TBCA. Thus, HeLa
cells were treated with cycloheximide (50 µg/ml) for 15 min,
30 min, and 60 min, and soluble protein extracts were analyzed
by 6% native-PAGE. We expected that the absence of input of
newly synthesized tubulin to TBCA, due to protein synthesis
inhibition, would mimic the effect of colchicine. However, we did
not observe a decrease in the TBCA/β-tubulin complex levels nor
in the free TBCA protein’s appearance during the time course of
cycloheximide treatment (Figure 2C). So, translation blockage
does not affect TBCA/β-tubulin complex levels and does not
cause the appearance of free TBCA. These results indicate that
the decrease in the amount of TBCA/β-tubulin in HeLa cells
treated with colchicine or nocodazole is not a consequence of
the inhibition of protein translation caused by the increase in
soluble tubulin as a consequence of the loss of the MTs network.
Also, the detection of free TBCA in cells treated with colchicine
cannot be ascribed to the absence of newly synthesized β-tubulin.
Thus, to further unequivocally show that the appearance of the
free TBCA protein observed is essentially the result of colchicine
treatment, we analyzed the soluble protein extracts of HeLa cells
simultaneously treated with cycloheximide and colchicine. For
this, we treated HeLa cells with cycloheximide (50 µg/ml) for
15 min before colchicine was added. This period provided the
time to inhibit protein synthesis prior to the action of colchicine.
From these cells, soluble protein extracts were prepared after 15,
30, and 60 min of exposure to both compounds and analyzed
in a 6% native-PAGE followed by western blot analysis using
specific antibodies against TBCA and β-tubulin (Figure 2). The
pattern of variation of TBCA/β-tubulin complex levels and free
TBCA protein appearance were like those obtained in cells only
treated with colchicine (compare Figures 1A1, 2A,C). Therefore,
colchicine causes the appearance of free TBCA. As anticipated,
protein synthesis inhibition does not interfere with colchicine’s
ability to promote MT depolymerization, which was confirmed
by indirect IF microscopy (Figure 2D). All samples analyzed
by non-denaturing gel electrophoresis (6% native-PAGE) were
simultaneously analyzed by 16.5% (w/v) Tricine–SDS–PAGE
followed by western blot analysis with antibodies directed to
TBCA and β-tubulin. As observed in Supplementary Figure 2,
colchicine in the presence of the translation inhibitor does not
cause dramatic changes in the levels of soluble TBCA and
β-tubulin (Supplementary Figure 3).
Overall, these results show that the absence of protein
synthesis and consequently the absence of an input of newly
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FIGURE 2 | Protein translation inhibition by cycloheximide does not lead to the detection of free TBCA in the cell extract. HeLa cells were treated with cycloheximide
to inhibit the protein translation and also with cycloheximide plus colchicine for 15, 30, and 60 min. In both treatments, time 0 min (control) corresponds to 15 min
after the cycloheximide addition. After each treatment, native protein extracts were prepared, and equal amounts of soluble protein (30 µg) were analyzed by
non-denaturing gel electrophoresis (6% Native-PAGE) followed by western blot with antibodies directed to TBCA (A) and β-tubulin (B). Representative images of the
native-PAGE show that under the cycloheximide treatment, free TBCA was not detected, and the levels of TBCA/β-tubulin are maintained but, the addition of
colchicine to cycloheximide leads to a decrease in TBCA/β-tubulin levels and detection of free TBCA after 60 min of colchicine treatment (A,C: for cycloheximide
treatment *p < 0.005, and for cycloheximide and colchicine treatment *p < 0.002). The graphs in panel (C) (cycloheximide and cycloheximide plus colchicine), show
the relative units in percentage of TBCA/β-tubulin complex and free TBCA levels in comparison to control (100%) cells. Statistical significance was calculated using a
t-test. And the p-values were determined in comparison to the time 0 min (control). The graphic bars are the mean s.d. (error bars) of three independent assays.
The α/β-tubulin levels are maintained during cycloheximide treatment but increase after addition of colchicine (B). For each treatment, the MT depolymerization was
confirmed by indirect immunofluorescence (D) using an antibody against α-tubulin (the DNA was stained with DAPI, scale bar 10 µm). The results observed in panel
(B) agree with the results showed in panel (C), where MTs can be detected with cycloheximide treatment but not with cycloheximide plus colchicine (C).
synthesized β-tubulin in the tubulin folding pathway does not
lead to the appearance of free TBCA nor affects the levels of the
TBCA/β-tubulin complex. This is the first indication that TBCA
is involved in heterodimer recycling from MT depolymerization.
This observation may finally elucidate the apparent incongruent
observations that TBCA is not essential for tubulin folding
in vitro (Tian et al., 1996) while its depletion causes cell death
(Nolasco et al., 2005).
TBCB and TBCE Are Not Able to
Dissociate Tubulin Heterodimers Bound
to Colchicine
Next, we aimed at elucidating the intriguing observation that
60 min of colchicine treatment leads to the appearance of
free TBCA. It is well-established that in vitro, TBCA is able
to accept β-tubulin from native tubulin heterodimers in the
presence of TBCE and TBCB (Kortazar et al., 2006, 2007).
Additionally, TBCB and TBCE cooperate to dissociate the tubulin
dimer and stabilize α-tubulin (Kortazar et al., 2007). Also,
colchicine binds irreversibly to tubulin dimers (Bhattacharyya
et al., 2008; Bhattacharya et al., 2016). Together, these data
strongly suggest that TBCA cannot interact with β-tubulin from
colchicine-bound to tubulin heterodimers, probably because
colchicine affects the ability of TBCB/TBCE to dissociate the
heterodimer. To test this hypothesis, we performed in vitro
tubulin dissociation assays in the presence of purified tubulin
cofactors: TBCE, TBCE plus TBCB, and TBCE plus TBCB
plus TBCA. In these assays, we incubated these cofactors with
native purified tubulin or with native tubulin purified after
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colchicine treatment. In the last case, tubulin was incubated
with colchicine for 1 h at room temperature in a proportion of
2 µM:48.2 µM, respectively (Banerjee and Luduena, 1992). After
incubating with colchicine, we purified the tubulin heterodimer-
colchicine complex by gel filtration chromatography to remove
the unbound colchicine. A similar purification protocol was
applied to tubulin not incubated with colchicine (control).
Figure 3A shows the chromatograms of the tubulin and tubulin-
colchicine gel filtration purification. The separation profiles are
very similar, indicating that colchicine did not affect tubulin
heterodimer behavior through gel filtration chromatographic
analysis. The tubulin heterodimer elutes at the second peak
(fractions 17–19) in accordance with its expected size (Fanarraga
et al., 2010b). Tubulin also appears in the column’s void volume
(first peak; fractions 6–9), suggesting the formation of large
aggregates (Fanarraga et al., 2010b). In each case, fractions
corresponding to tubulin heterodimers peak (17–19 fractions in
both cases) were pooled. These fractions were used to perform
tubulin heterodimer dissociation assays (Kortazar et al., 2006).
For this purified tubulin and tubulin-colchicine heterodimers
(2.2 µg/reaction) were incubated with or without TBCE (1.5
µg/reaction), TBCB (0.6 µg/reaction) and TBCA (5 µg/reaction),
according to the table in Figure 3B. The products of tubulin
heterodimer dissociation assays were analyzed by native-PAGE,
and the gel was stained with Coomassie brilliant blue. Under
these conditions, tubulin incubation with TBCE and TBCB
leads to decreased tubulin heterodimers’ concentration due to
tubulin heterodimer dissociation, which agrees with what was
previously described by Kortazar et al. (2006). As expected
(Kortazar et al., 2006; Carranza et al., 2013), when TBCA is
included in the reaction, a new band corresponding to TBCA/β-
tubulin complex is detected in the gel. However, when a similar
assay is performed using tubulin pre-incubated with colchicine,
the decrease in the α/β-tubulin heterodimer is not observed
(Figure 3B). Consequently, in the presence of TBCA, we did
not detect the TBCA/β-tubulin complex. These results clearly
indicate that the binding of colchicine to tubulin heterodimer
blocks the ability of TBCE and TBCB to dissociate the tubulin
heterodimer, which leaves TBCA free.
These data are supported by a structural prediction based
on the comparison between the α/β-tubulin-colchicine and α/β-
tubulin 3D structure in association with TBCB and TBCE as
presented in Figure 4. This analysis was based on the fact
that the tubulin dimer dissociation by TBCB/TBCE involves a
ternary complex TBCE/TBCB/α-tubulin (Carranza et al., 2013;
Serna et al., 2015). TBCE and TBCB have a cytoskeleton-
associated protein glycine-rich (CAP-Gly) and a UBL domain
(Grynberg et al., 2003; Serna and Zabala, 2016). The TBCB
intermediate region has a short coiled-coil region (CC), whereas
that of TBCE has a leucine-rich repeat (LRR) domain. The
molecular architecture of this complex proposed by Serna et al.
(2015), predicts that the TBCE-TBCB complex, hold by the
interaction between the CAP-Gly domains, bind the α-tubulin
monomer of the α/β-tubulin heterodimer and dissociate it
presumably by pushing the TBCE LRR domain toward the
β-tubulin monomer and distorting the α/β-tubulin interface.
Also, the colchicine molecule binds at the α/β-tubulin interface,
next to the α-tubulin GTP binding pocket (Prota et al.,
2014). The comparative analysis of α/β-tubulin-colchicine and
α/β-tubulin 3D structures show that, in the presence of the
colchicine, the α/β-tubulin interface adopts a closer conformation
(Figure 4C). This agrees with the experimental observations
that colchicine binding induces a conformational change of
tubulin (Garland, 1978; Detrich et al., 1981; Andreu and
Timasheff, 1982). Therefore, the presence of the colchicine
could impair the α/β-tubulin heterodimer dissociation by
TBCB/TBCE by stabilizing the α/β-tubulin interface and make
it resist the mechanical force applied by the LRR domain of
TBCE (Figure 4D).
Again, the overall data strongly supports that an important
role of TBCA in HeLa cells is to accept β-tubulin resulting from
α/β-tubulin heterodimer that arises from MT depolymerization
and is dissociated by the TBCB/TBCE machine or by the
TBCD cofactor (Martín et al., 2000). Therefore, in vivo, TBCA’s
role is articulated with TBCB/TBCE activity to recycle the
tubulin heterodimers and most probably to control their quality.
The three tubulin cofactors also probably manage tubulin
degradation, with TBCA avoiding the toxic effect of β-tubulin
during the recycling process. These data also explain why the
depolymerization of MTs by colchicine is irreversible in the
presence of saturated doses of this molecule. Tubulin-colchicine
heterodimers are condemned to be part of a pool of heterodimers
that cannot polymerize because they cannot be dissociated
and then recycled.
Studies of Overexpression and Depletion
Support TBCA Main Role in β-Tubulin
Recycling
The observation that an important role of TBCA is to
bind β-tubulin during tubulin heterodimer recycling raised
the question of whether TBCA levels may affect the tubulin
dissociation rate by TBCB/TBCE, regulating, therefore, the
availability of tubulin heterodimers competent to polymerize and
also MT dynamics. It is conceivable, therefore, that if in vivo
TBCA concentration is critical, it would regulate the efficiency
of tubulin heterodimer dissociation by TBCB/TBCE. On other
words, low levels of TBCA in the context of accentuated MT
depolymerization could impair tubulin heterodimer dissociation
by TBCB/TBCE since β-tubulin cannot be accepted, becoming
toxic. This would implicate that in this background β-tubulin is
driven to degradation. Consequently, we performed experiments
where we modulated TBCA levels either by promoting its
overexpression via pcDNA3-TBCA transfection (Figures 5A,B)
or by knocking down the TBCA gene with a specific siRNA (as
in Nolasco et al., 2005; Figures 5C,D). Western blot analysis of
TBCA levels in control and TBCA siRNA-treated cells shows
that TBCA levels decreased by about 48 ± 8% in TBCA-silenced
cells. Hsp70 was used as loading control (Figure 5D). 24 h
after transfections, native soluble protein extracts were prepared
from control and TBCA overexpressing or depleted cells and
analyzed either by native-PAGE or Tricine–SDS–PAGE followed
by western blot using antibodies against TBCA, α- and β-
tubulin (Figure 5). TBCA overexpression results show a dramatic
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FIGURE 3 | In vitro dissociation assays reveal that TBCB and TBCE are not able to dissociate the tubulin-colchicine heterodimer which leaves TBCA free. (A) After
the assay of colchicine binding to tubulin, tubulin-colchicine heterodimers were purified by gel filtration to remove the unbounded colchicine molecules and
aggregated misfolded tubulin. As a control the same amount of tubulin was also incubated without colchicine and purified by gel filtration. Chromatographic elution
profiles obtained at 280 nm of absorbance from a gel filtration analysis of control and tubulin heterodimers incubated with colchicine are very similar, presenting three
prominent peaks: the first one corresponds to tubulin aggregates, the second one to tubulin heterodimers, and the third one to small molecules. The colchicine
molecule bound to tubulin heterodimer did not affect the behavior of tubulin heterodimer in gel filtration. Each peak of tubulin and tubulin-colchicine heterodimers
were pooled (17–19 fractions). (B) Purified tubulin and tubulin-colchicine heterodimers, from pooled fractions (2.2 µg/reaction), were incubated at 30◦C for 30 min
with or without TBCE (1.5 µg/reaction), TBCB (0.6 µg/reaction) and TBCA (5 µg/reaction), according to the table, to perform tubulin heterodimer dissociation assays.
The tubulin heterodimer dissociation assays were analyzed by non-denaturing gel electrophoresis (6% native-PAGE) and stained with Coomassie brilliant blue. The
tubulin incubation with TBCE and/or TBCB lead to a decrease in the tubulin heterodimers amount due to tubulin heterodimer dissociation, as previously described
(Kortazar et al., 2006; Carranza et al., 2013). When TBCA is also present, we detected a new band in the gel that corresponds to TBCA/β-tubulin (Kortazar et al.,
2006; Carranza et al., 2013). When colchicine is bound to tubulin, TBCE and/or TBCB cannot dissociate the tubulin heterodimer. Consequently, in the presence of
TBCA, we did not detect the presence of TBCA/β-tubulin complex. Colchicine impairs the tubulin dissociate activity of TBCE/TBCB, leaving TBCA free.
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FIGURE 4 | Colchicine could impair TBCE-TBCB complex function in the α/β-tubulin heterodimer dissociation process by stabilizing the α-tubulin/β-tubulin interface.
(A) Two associated α/β-tubulin heterodimers stabilized by the colchicine molecule (green surface). The GTP form of the α-tubulin monomer and the GDP form of the
β-tubulin are displayed in blue and yellow (GTP and GDP surfaces are shown in purple and magenta, respectively), PDB ID 4O2B. (B) Zoom-in view of colchicine
(green) at the α/β-tubulin interface, next to the α-tubulin GTP binding pocket, PDB ID 4O2B (Prota et al., 2014). (C) Comparison of the free α/β-tubulin heterodimer
(α-tubulin in purple and β-tubulin in gray, PDB ID 1JFF; Löwe et al., 2001), with the α/β-tubulin heterodimer stabilized by colchicine (α-tubulin in blue and β-tubulin in
yellow, PDB ID 4O2B; Prota et al., 2014) by aligning the α-tubulin monomers. The presence of colchicine affects the α/β-tubulin interface geometry, as shown with
the dash lines. (D) The complex TBCE-TBCB, hold by the interaction between the CAP-Gly domains (TBCE CAP-Gly domain surface in green and TBCB CAP-Gly
domain surface in gray), binds the α-tubulin monomer of the α/β-tubulin heterodimer (blue, EMDB-2447; Serna et al., 2015) pushing the TBCE LRR domain (domain
surface in coral) toward the β-tubulin monomer (yellow) and distorting the α/β-tubulin interface. The presence of colchicine (green surface) could impair α/β-tubulin
heterodimer dissociation by stabilizing the α/β-tubulin interface, making it resistant to the mechanical force applied by the LRR domain.
increase in free TBCA and TBCA/β-tubulin complex levels in
native gels (Figure 5A) and a clear increase in total soluble TBCA
amount can be observed in SDS denaturing gels (Figure 5B).
On the other hand, the levels of α/β-tubulin heterodimer
slightly decrease in response to the increased TBCA levels
(Figure 5A). This small decrease in heterodimer may result
from an increased dissociation rate of the heterodimer by
TBCB/TBCE, which agrees with the increased levels of
TBCA/β-tubulin complex (see Figure 5A) and absence of
variation of total soluble β-tubulin levels. However, the results
did not support the observation that TBCA improves the in vitro
dimerization rate of α/β-tubulin (Fanarraga et al., 1999) since
we do not observe an increase in tubulin heterodimer. This
observation confirms once more that TBCA plays a critical role
in heterodimer recycling but not in the tubulin folding route. On
the other hand, TBCA siRNA significantly decreases the amount
of native α/β-tubulin heterodimer (Figure 5C) in line with our
previous results showing an accentuated decrease of α- and β-
tubulin in HeLa and MCF-7 cell lines extracts in response to
TBCA depletion (Nolasco et al., 2005). Probably this is due to the
continuous tubulin heterodimer dissociation by TBCB/TBCE to
be recycled. Since there is not enough TBCA to accept β-tubulin,
both tubulins are probably destined to degradation. Altogether,
these results indicate that the levels of TBCA are essential to
regulate the rate of tubulin heterodimer dissociation/recycling
by TBCB/TBCE. These results also strengthen the role of TBCA
as a major component of the recycling/degradation pathway of
the α/β-tubulin heterodimer, weakening its eventual role in the
folding of newly synthesized β-tubulin in vivo.
TBCA Is Abundant in Insoluble Protein
Extracts of the Heart
Colchicine has been consistently used in the treatment of acute
and recurrent pericarditis (Adler et al., 2015). Moreover, other
potential therapeutic uses for colchicine are the prevention of
Atrial Fibrillation (AF) reappearance after cardiac surgery or
AF ablation (Calkins et al., 2017), as well as in patients with
coronary artery disease (Nidorf et al., 2014, 2020; Deftereos
et al., 2015) and chronic heart failure. In this view and guided
by our results showing that: (i) colchicine impairs tubulin
heterodimer dissociation by TBCB/TBCE, leaving TBCA free of
β-tubulin; (ii) TBCA has a regulatory role in tubulin heterodimer
recycling and (iii) altered levels of TBCA have been associated
with human diseases (see Table 1), we analyzed the pattern of
TBCA expression in different mouse organs. Previous analyses
showed that TBCA is a soluble protein highly expressed in testis
and in brain (Fanarraga et al., 1999) but no information is
available regarding expression of TBCA in the heart. Therefore,
we have prepared total protein extracts from the heart, brain,
kidney, liver, lung, and testis of adult mice. The extracts were
fractionated in soluble and insoluble fractions and analyzed
by 16.5% (w/v) Tricine–SDS–PAGE followed by western blot
using specific antibodies against TBCA, α-tubulin, and β-actin
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FIGURE 5 | Native tubulin heterodimers levels decrease in response to TBCA overexpression and TBCA siRNA. HeLa cells were transfected with TBCA-pcDNA3
(TBCA-OE), and control cells were transfected with empty pcDNA3. 24 h after transfection, native protein extracts were prepared. Equivalent amounts of protein
soluble fraction (30 µg) were analyzed by non-denaturing gel electrophoresis Native-PAGE) (A) and by 16.5% Tricine–SDS–PAGE (B) followed by Western blot with
antibodies directed to TBCA and β-tubulin. (A) In native gels, TBCA overexpression is clearly detected by the increase of the amount of free TBCA and the
TBCA/β-tubulin complex. Tubulin heterodimer levels decrease when TBCA is overexpressed. (B) The denaturing analysis using Tricine–SDS–PAGE showed that
β-tubulin levels do not change in response to TBCA overexpression. 24 h after TBCA siRNA transfection (see Nolasco et al., 2005 for details and controls), protein
extracts were prepared. Equal amounts of protein soluble fraction (30 µg) were analyzed by non-denaturing gel electrophoresis (6% Native-PAGE) (C) and by 16.5%
Tricine–SDS–PAGE (D), to check the TBCA knockdown efficiency, followed by western blot with antibodies against β-tubulin, TBCA and Hsp70. (C) TBCA
knockdown also causes a decrease in the tubulin heterodimer amount. (D) Cells transfected for 24 h with TBCA siRNAs show a reduction in levels of TBCA. Hsp70
protein levels were used as a loading control.
(Figure 6). Similar to what was observed by Fanarraga et al.
(1999), TBCA is extremely abundant in the soluble fraction
of testis followed by the brain, and α-tubulin and β-actin are
detected in all tissue-specific samples (Figure 6A). However, in
the insoluble fraction, TBCA is extremely abundant in the heart,
followed by the testis. As expected, α-tubulin is mainly detected in
the brain and testis, and β-actin is present in all samples but much
more abundant in the heart, followed by the lung. These results
are surprising because TBCA is assumed to be a soluble protein
pinpointing for a possible contamination of the insoluble fraction
with soluble proteins. This hypothesis is, however, discarded by
the observation that in the heart TBCA is barely detected in
the soluble fraction. We could still consider that our protein
extraction was inefficient in heart cells lysates, explaining the low
levels of TBCA observed in the soluble fraction and its retention
in the insoluble extract. However, the detection of α-tubulin and
even actin excludes this hypothesis (Figures 6A,B). Therefore,
TBCA should be associated with membranes and/or cellular
organelles present in insoluble extracts.
DISCUSSION
The dynamic behavior of MTs is critical for the myriad
functions these polymers play in eukaryotic cells. MT functions
require a pool of tubulin heterodimers competent to polymerize
from newly synthesized tubulins and from recycling tubulin
heterodimers from pre-existing MTs. These processes are
complex and assisted by a dedicated set of tubulin cofactors.
Colchicine is a natural anti-mitotic agent with clinical relevance
in treating inflammatory diseases that is known to irreversibly
affect MT polymerization and dynamics. Although anti-mitotic
agents’ action in MT assembly is well-established, their impact on
tubulin heterodimers’ recycling pathway is mainly unknown.
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TABLE 1 | Altered TBCA expression in several diseases.
Disease Organ TBCA expression Molecule Reference







Breast Overexpression Protein Fonseca-Sánchez
et al., 2012
Stomach Overexpression mRNA Malta-Vacas et al.,
2009
Alzheimer Brain Underexpression Protein Zhang et al., 2018
Parkinson Brain Overexpression Protein Werner et al., 2008
Osteoporosis Bone Underexpression mRNA Xia et al., 2017
Ankylosing
spondylitis
Blood Hypomethylation DNA Coit et al., 2019
In the present work, we report that colchicine treatment
of HeLa cells, but not cold-shock or nocodazole, causes the
appearance of free TBCA in protein extracts (Figure 1). This
is an unexpected observation since, in all situations that we
have studied, we have always found TBCA in a complex
with β-tubulin. Moreover, this was accompanied by a marked
decrease of the TBCA/β-tubulin complex. Our data also shows
that the appearance of free TBCA cannot be ascribed to the
interruption of the tubulin folding pathway. Indeed, protein
translation inhibition by cycloheximide does not lead to free
TBCA, and colchicine is still able to cause the appearance
of free TBCA in its presence (Figure 2). These assays clearly
show that not only colchicine interferes with TBCA’s role, but
TBCA seems to receive β-tubulin polypeptides mostly from the
tubulin heterodimer recycling pathway. The current model of
α/β-tubulin heterodimer assembly (Lopez-Fanarraga et al., 2001;
Serna and Zabala, 2016) predicts that, if the input of newly
synthesized β-tubulin is inhibited by the absence of translation,
TBCA becomes free, at least partially. In the recycling pathway
of the α/β-tubulin heterodimers, their dissociation by TBCE and
TBCB leads to a ternary complex of TBCB/TBCE/α-tubulin,
whereas β-tubulin is stabilized by TBCD or TBCA (Carranza
et al., 2013; Serna et al., 2015). Noteworthy, in vitro, the
TBCA/β-tubulin complex is stable and easy to be detected
(Kortazar et al., 2006). Therefore, the appearance of free
TBCA is probably the result of compromised TBCB/TBCE
dissociation activity due to colchicine. Our tubulin heterodimer
dissociation in vitro assays (Figure 3) unequivocally confirm
this hypothesis, showing that, in the presence of colchicine, the
TBCB/TBCE dissociation machine is unable to dissociate the
tubulin heterodimer (Figure 3). Given these results, the decrease
in the amount of TBCA/β-tubulin complex during the colchicine
treatment is easily explained by the absence of β-tubulin that
cannot be released by tubulin cofactors from the dimer, resulting
in the detection of free TBCA.
Colchicine and nocodazole are both microtubule binding
drugs that targets the β-tubulin subunit at a pocket close
to the α-tubulin/β-tubulin heterodimer interface. It has been
proposed that both compounds disrupt the MT dynamics by
preventing the curve-to-straight conformational change of the
α/β-tubulin heterodimer upon GTP hydrolysis (Wang et al.,
2016). Our structural prediction of the α/β-tubulin-colchicine
3D structure associated with TBCB/TBCE (Figure 4), indicates
that, in the presence of the colchicine, the α/β-tubulin interface
might adopt a closer and more stable conformation, able to
resist the mechanical force applied by the LRR domain of
TBCE, which could explain the inability of TBCB/TBCE to
dissociate the tubulin heterodimer. In the case of nocodazole,
the molecule is structurally very different of colchicine and show
different binding dynamics. Firstly, the nocodazole molecule is
FIGURE 6 | TBCA is present in a high amount in mouse insoluble protein extracts from the heart. Soluble (A) and insoluble (B) protein extracts from mouse organs
(heart, brain, kidney, liver, lung, and testis) were prepared and analyzed on 16.5% (w/v) Tricine–SDS–PAGE followed by western blot with antibodies against TBCA,
α-tubulin, and β-actin. Soluble protein extracts were quantified, and equal protein amounts (100 µg) were analyzed. Insoluble protein extracts were solubilized with 8
M urea and diluted 1:2 in loading buffer and, 20 out of 200 µl were analyzed. (A) The analysis showed that TBCA was more abundant in testis and brain. α-tubulin
and β-actin are detected in all organs. (B) The insoluble protein extracts show that TBCA is more abundant in the heart and testis. α-tubulin is mainly detected in
testis and brain, and β-actin is detected in all organs. The approximate molecular mass of the proteins is indicated on the left side of the panels.
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placed deeper in the β-tubulin monomer than the colchicine
and it does not seem to interact with the α-tubulin monomer
(Aguayo-Ortiz et al., 2013; Wang et al., 2016). Secondly, while
colchicine is irreversibly bound to the β-tubulin and its effects
on MT polymerization is also irreversible; nocodazole is a
rapidly reversible inhibitor. Because the α/β-tubulin heterodimer
conformation in the presence of colchicine is very similar to that
in the presence of nocodazole, it is tempting to think that the
nocodazole bound-heterodimer would be also resistant to the
TBCE, TBCB dissociation activity. However, nocodazole results
are distinct from those originated by colchicine (Figure 1). It is
plausible that the resistance to the mechanical force applied to the
heterodimer by the tubulin cofactors might require a more stable
drug binding-state of it to be evaluated. Although the α/β-tubulin
heterodimer dissociation kinetics remains to be quantified, it is
reasonable to propose that the dissociation activity of the TBCE
and TBCB cofactors may be slower than the binding kinetics
of nocodazole. In bulk, the dissociation activity taking place
on free heterodimers would hinder detection of the activity on
nocodazole bound heterodimers.
It was known that in in vitro tubulin dissociation assays
performed in the presence of TBCB and TBCE, but in the
absence of TBCA, β-tubulin becomes unstable and aggregates
(Kortazar et al., 2006). The formation of those aggregates might
be avoided by the addition of TBCA (Kortazar et al., 2006). These
results motivated us to investigate how excess or deficiency in
TBCA levels affect tubulin heterodimer dissociation by analyzing
the levels of the TBCA/β-tubulin complex. Interestingly, and
contrary to our prediction, TBCA overexpression leads to a
decrease of the α/β-tubulin heterodimer levels (Figure 5A).
Strikingly, TBCA depletion (Figure 5C) also causes the decrease
of α/β-tubulin heterodimer (Nolasco et al., 2005) and present
work). TBCA overexpression results support the evidence that
TBCA plays an important role in the recycling pathway of the
tubulin heterodimer. Indeed, excess TBCA does not lead to an
increase in tubulin dimerization. The observed decrease of α/β-
tubulin heterodimer amounts, together with the increase in the
TBCA/β-tubulin complex, strongly suggests that, when more
TBCA is available, the tubulin heterodimer proceeds through
the recycling route. In the case of cells treated with TBCA
siRNA, the diminished levels of the α/β-tubulin heterodimer
are possibly the consequence of driving tubulin to degradation,
since the recycling pathway cannot be completed due to low
TBCA levels. Therefore, it is conceivable that, in vivo, TBCA
concentration determines tubulin fate being it recycling or
degradation. It was proposed that the UBL domains of both
TBCE and TBCB in the dissociation complex remain free and
exposed, protruding from opposite positions in the central mass
of the complex (Serna et al., 2015). This observation strongly
suggests that both domains could be involved in the degradation
of α-tubulin subunit by the proteasome, while no degradation
mechanism was previously described for β-tubulin. In our study
we show that β-tubulin is degraded in cells depleted of TBCA,
indicating that TBCD, known to dissociate the α/β-tubulin
heterodimer by itself and to stabilize the β-tubulin (Martín
et al., 2000), does not seem to have a prominent role in its
recycling pathway.
In the last years, numerous studies have shown that altered
levels of TBCA expression are associated with human diseases
like cancer, neurodegenerative diseases, osteoporosis, and
Ankylosing spondylitis (Table 1). Strikingly the human diseases
associated with the other TBCs are mainly due to mutations
in genes encoding these proteins (review Serna and Zabala,
2016). According to our results, the altered levels of TBCA
will affect the α/β-tubulin heterodimer recycling/degradation,
which will impact MT cytoskeleton dynamics and remodeling.
Nothing is known about the role of TBCs in the incorporation of
distinct tubulin isotypes in different MT classes, or alternatively
in response to specific signals. We envisage that the recycling
pathway of tubulins will have a prominent role in altering
the biochemical/biophysical properties of MTs by allowing the
polymerization of different tubulin isotypes.
Our results also show that TBCA is enriched in insoluble
protein extracts obtained from adult heart mice (Figure 6).
At first glance, this observation is unexpected, but a detailed
analysis of the cardiomyocyte cytoskeleton reveals that MTs
in crosstalk with actin and intermediate filaments play specific
roles in sustaining the cardiac contractile function (Kuznetsov
et al., 2020). In cardiomyocytes, MTs are known to be involved
in the intracellular traffic and the transmission of mechanical
signals, in the shaping of membrane systems, and in the spatial
organization of myofibrils and organelles (Caporizzo et al., 2019).
Probably, the demanding roles of MTs in these cells, such
as mechanical transduction, may require intense recycling of
tubulin heterodimers, explaining the abundance of TBCA. In
fact, it was recently shown that MTs exchange tubulin dimers at
lattice defects sites induced by mechanical stress (Schaedel et al.,
2015; Aumeier et al., 2016). Indeed, TBCD was downregulated
by arterial shear stress (Schubert et al., 2000). These events may
occur spontaneously during MT polymerization due to MT-
severing enzymes or other unknown factors (Schaedel et al., 2015;
Aumeier et al., 2016). The specific roles of TBCs, including the
role of TBCA shown in this work, indicate that these molecules
are excellent candidates to be involved in these stress responses.
It is still intriguing the observation of high levels of TBCA
in the insoluble protein extracts of the heart tissue. In cardiac
cells, MTs are located close to the nuclear envelope, in the
transverse (T)-tubules membrane, and at the mitochondrial
membrane (Caporizzo et al., 2019). It was observed that
tubulin heterodimers are bound to and regulate the voltage-
dependent anion channel (VDAC) in mitochondria (Carré
et al., 2002). This attachment that seems to be established
through a specific β-tubulin isotype (βII-tubulin), is strong
enough to maintain β-tubulin in an ordered striated distribution
pattern that colocalizes with the mitochondria, even after MT
depolymerization and cells permeabilization (Rappaport and
Samuel, 1988; Guerrero et al., 2010). Moreover, it was described
that in cardiomyocytes, about 70% of total tubulin is present
in MTs, whereas 30% occurs as free tubulin heterodimers
(Tagawa et al., 1998; Hein et al., 2000; Kostin et al., 2000).
Therefore, we can speculate that TBCA may be associated with
β-tubulin in these localizations playing an unknown function,
which could justify the enrichment of TBCA in the insoluble
fraction. Alternatively, the canonical role of TBCA/β-tubulin
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complex in β-tubulin recycling may be performed in situ in close
association with membranes.
Colchicine is a therapeutical hallmark in pericardial diseases
characterized by densification of the MT network, leading to
increased cell stiffness (Hein et al., 2000). It has been assumed that
colchicine has a beneficial role in cardiomyocytes via decreasing
MT mass and altering MT dynamics (Hein et al., 2000). Our
work shows, for the first time, that colchicine affects the tubulin
recycling process by inhibiting tubulin heterodimer dissociation,
which leads to the decrease in the amount of TBCA/β-tubulin
complex, resulting in free TBCA in the cell. As such, our results
open the possibility that TBCA/β-tubulin complex may have
unknown roles in cardiomyocytes. Future studies are required
to elucidate the consequences of free TBCA in cells and overall
colchicine mechanism of action.
From this work, TBCA emerges as an important protein
in the recycling/degradation of β-tubulin and, consequently, in
the regulation of MT dynamics. Indeed, this idea is strongly
supported by the fact that TBCA has been associated with
different human diseases where its levels are altered (Table 1).
Although providing an important contribution, our results
suggest that the role of TBCA and/or TBCA-tubulin complex’s
role in eukaryotic cells require further validation from in vitro,
and, most importantly, in vivo studies.
MATERIALS AND METHODS
Cell Culture
HeLa human tumor cell line, was cultured in a 5% CO2
humidified atmosphere at 37◦C as exponentially growing sub-
confluent monolayers in Dulbecco’s modified Eagle’s medium
(DMEM) with Glutamax (Invitrogen; Thermo Fisher Scientific,
Inc., Waltham, MA, United States), supplemented with 10% fetal
calf serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham,
MA, United States) and non-essential amino acids (Invitrogen;
Thermo Fisher Scientific, Inc., Waltham, MA, United States).
The MT depolymerizing experiments were done after 15, 30,
and 60 min incubation with either 5 µM colchicine (Sigma, St.
Louis, United States), or 30 µM nocodazole (Sigma, St. Louis,
United States) or with cold shock (culture media at 4◦C was
added to the cells and the cell plates were put on ice during
the treatment (Weisenberg, 1972; Shelanski et al., 1973). The
concentrations of colchicine and nocodazole used in this work
aimed at causing an accentuated and rapid increase of tubulin
heterodimers due to MT depolymerization and are similar to
those already used in other cell lines (Breitfeld et al., 1990;
Karbowski et al., 2001). Translation inhibition was carried out
by the cycloheximide (Sigma, St. Louis, United States) treatment
(50 µ g/ml).
TBCA siRNA and TBCA overexpression transfection
experiments were performed according to our previous results
(Nolasco et al., 2005; Kortazar et al., 2007).
Protein Extraction From HeLa Cells
For native protein extracts, cells were rinsed twice with PBS.
During the second PBS wash, cells were removed from culture
plates by scraping and then centrifuged at 3,500 g for 5 min
at room temperature (RT). Then, PBS was discarded, and
the cell pellets were resuspended in lysis buffer (100 mM
MES, pH 6.7 (Sigma, St. Louis, United States); 1 mM
MgCl2 (Merck, Darmstadt, Germany); 1 mM EGTA (Sigma,
St. Louis, United States); 0.1 mM GTP (Sigma, St. Louis,
United States); 0.2 mM DTT (Sigma, St. Louis, United States)
and 0.1 mM PMSF (Sigma, St. Louis, United States), containing
a protease inhibitors cocktail (Thermo Fisher Scientific, Inc.,
Waltham, MA, United States). Total protein extracts were
obtained by homogenizing samples at room temperature or 4◦C
mechanically, using a potter-homogenizer. Cellular lysates were
centrifuged at 14,000 g for 30 min at RT. The supernatants
were recovered (soluble fraction). An important note is that,
except for samples submitted to cold shock, all protein extracts
were prepared at RT and RT solutions/buffers to avoid MT
depolymerization due to cold solutions/buffers normally used to
prevent protein degradation.
After protein quantification by Bradford (Bio-Rad, California,
United States), equal amounts of soluble protein extracts (30 µg)
were separated on non-denaturing gel electrophoresis [6% (w/v)
Native-PAGE] (Zabala and Cowan, 1992; Fontalba et al., 1993).
Protein extracts from TBCA siRNA and TBCA overexpression
experiments were also analyzed on a 16.5% (w/v) Tricine–SDS–
PAGE (Schägger and von Jagow, 1987).
Protein Extraction From Different Mouse
Organs
Mouse organs were pulverized cryogenically in liquid nitrogen
using a mortar and pestle for grinding frozen tissue. 200 µl of
lysis buffer [1% NP40; 50 mM HEPES, pH 8 (Sigma, St. Louis,
United States); 200 mM NaCl (Sigma, St. Louis, United States);
5 mM EDTA (Sigma, St. Louis, United States); 0.2 mM DTT
(Sigma, St. Louis, United States) and 0.1 mM PMSF (Sigma, St.
Louis, United States)], containing a protease inhibitors cocktail
(Thermo Fisher Scientific, Inc., Waltham, MA, United States)
were added to 150 mg of the pulverized organ and homogenized
using a potter-homogenizer. Cellular lysates were removed and
centrifuged at 14,000 × g for 90 min at 4◦C. After protein
quantification by Bradford (Bio-Rad, California, United States),
equal amounts of soluble protein extracts (100 µg) were separated
on 16.5% (w/v) Tricine–SDS–PAGE (Schägger and von Jagow,
1987). 100 µl of 8 M urea were added to the pellets of the
insoluble fraction. The insoluble protein extracts were diluted
1:2 in loading buffer, and 20 µl were analyzed on 16.5% (w/v)
Tricine–SDS–PAGE (Schägger and von Jagow, 1987).
Western Blot Analysis
Westerns blots were performed using the rabbit polyclonal
serum against TBCA (1:5,000) (Llosa et al., 1996), the mouse
monoclonal antibody against β-tubulin (1:1,000) (clone TUB
2.1, Sigma, St. Louis, United States), the mouse monoclonal
antibody against α-tubulin (1:1,000) (clone DM1A, Sigma, St.
Louis, United States) and the rabbit monoclonal antibody against
β-actin (1:2,000) (Sigma, St. Louis, United States). Secondary
antibodies against rabbit and mouse (Jackson Immuno Research)
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were used at 1:4,000. The immunostaining was carried out using
the ECL technique (GE Healthcare). The presented results are
representative of at least three independent experiments.
Fluorescence Microscopy
For immunofluorescence microscopy studies, cells were washed
twice with PBS (Invitrogen; Thermo Fisher Scientific, Inc.,
Waltham, MA, United States) and then fixed in 3.7% (w/v)
paraformaldehyde (Merck, Darmstadt, Germany) in PBS for
10 min at room temperature. They were then washed twice
with PBS for 5 min and permeabilized for 2 min using 0.1%
(v/v) Triton X-100 (Sigma, St. Louis, United States) in PBS.
After rinsing twice for 5 min in PBS and once in PBS-
0.1% (v/v) Tween-20 (Merck, Darmstadt, Germany), cells were
blocked in 3% (w/v) BSA (Calbiochem; Sigma, St. Louis,
United States) for 15 min. Next, cells were incubated with the
mouse monoclonal α-tubulin antibody (clone DM1A, Sigma,
St. Louis, United States) at 1:200 in the same solution for
60 min. Samples were washed twice in PBS for 5 min and
once in PBS-0.1% (v/v) Tween-20. Secondary antibody Alexa
Fluor 488-conjugated goat anti-mouse IgG at 1:500 (Molecular
Probes; Invitrogen; Thermo Fisher Scientific, Inc., Waltham,
MA, United States) was incubated for 60 min in the same
solution. The preparations were washed twice in PBS for 5 min
and once in PBS-0.1% (v/v) Tween-20. DNA was stained with
DAPI (1 µg/µl) in PBS for 1 min. The preparations were
washed in PBS and mounted in MOWIOL 4-88 (Calbiochem;
Sigma, St. Louis, United States) mounting medium supplemented
with 2.5% (w/v) DABCO (Sigma, St. Louis, United States).
Cells were examined with a fluorescence microscope (Leica
DMRA2), and image acquisition was performed with a cooled
CCD camera and MetaMorph Imaging Software (Universal
Imaging Corporation). Image processing was carried out with
ImageJ Software.
Protein Production for in vitro Assay
Human TBCA was cloned and purified from Escherichia
coli cells (Llosa et al., 1996). Human TBCE and TBCB
were purified from insect cells infected with recombinant
baculovirus and E. coli cells, respectively (Kortazar et al., 2007).
Tubulin dimers were isolated and purified from bovine brain
(Avila et al., 2008).
Tubulin Purification After Colchicine
Incubation
The in vitro assay of colchicine binding to tubulin was done
under conditions where the drug was present in large excess
over tubulin (Banerjee and Luduena, 1992). Bovine brain purified
tubulin (60 µM) was incubated with colchicine (1.4 mM) for
1 h at room temperature, and tubulin-colchicine heterodimers
were purified by gel filtration (Superdex 200 PC 3.2/30) using
a Smart System (Amersham Pharmacia Biotech) to remove
unbounded colchicine. The elution buffer used was 0.1 M
MES pH 6.7, 1 mM MgCl2, 1 mM EGTA, 25 mM KCl and
0.1 mM GTP. Fractions of 50 µl were eluted at 40 µl/min. As
a control, the same amount of bovine brain purified tubulin
was also incubated for 1 h at room temperature, without
colchicine, followed by gel filtration purification. Each peak of
tubulin and tubulin-colchicine heterodimers were pooled (17–
19 fractions).
Tubulin Dimer Dissociation Assay
Purified tubulin and tubulin-colchicine heterodimers, from
pooled fractions (2.2 µg), were incubated at 30◦C for 30 min with
or without TBCE (1.5 µg/reaction), TBCB (0.6 µg/reaction) and
TBCA (5 µg/reaction) in buffer 0.1 M MES pH 6.7, 1 mM MgCl2
and 0.1 mM GTP, to perform tubulin heterodimer dissociation
assays. These assays were analyzed on 6% (w/v) native-PAGE
(Zabala and Cowan, 1992; Kortazar et al., 2007) and stained with
Coomassie brilliant blue.
Statistical Analysis
The experiments were performed at least three times and the
results were expressed as means ± S.D. Differences between the
data were tested for statistical significance by t-test. P< 0.05 were
considered statistically significant.
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